BioRestorative Prices $1.085 Million Direct Offering at $1.60 With Concurrent Warrants

Overview

• BioRestorative entered definitive agreements to sell 678,125 common shares at $1.60 per share for expected gross proceeds of $1.085 million, with closing targeted for on or about October 8, 2025.
• In a concurrent private placement, investors will receive 508,594 unregistered warrants covering 75% of the shares sold, exercisable in six months for five years at an exercise price of $2.75.
• The company plans to use net proceeds to advance BRTX-100 clinical trials, support ThermoStem preclinical research, develop its biocosmeceutical platform, and fund general corporate needs.
• Alere Financial Partners served as exclusive placement agent, with the share offering conducted under a Form S-3 shelf declared effective by the SEC on February 14, 2023, and the warrants issued under Section 4(a)(2)/Regulation D.
• Market coverage noted a short-term rebound in BRTX shares to a $1.55 close on October 3, and the company highlighted participation by healthcare-focused institutions, including its largest shareholder, with executives also investing.